NCT06616532
PM8002 in Combination With Paclitaxel Compared With Chemotherapy as Second-line Treatment in Small Cell Lung Cancer
At risk: Primary completion moved at least 3 months later.
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 6 versions: 6 with changes below. See every version on ClinicalTrials.gov ↗
Notable Eligibility criteria expanded, about 20 words Show 4 more changesShow less
- Primary completion pushed from Jan 25, 2027 to May 2027
- Study completion date: Dec 25, 2028 to Dec 2028
- Secondary endpoints: details revised at 2 of 11 entries
- Site details revised at 9 of 45 sites
- Minor Trial status: Recruiting to Active, Not Recruiting
- Site details revised at 45 of 45 sites
- Minor Site details revised at 1 of 45 sitesv4
- Minor Site details revised at 2 of 45 sitesv3
- Notable Trial status: Not Yet Recruiting to Recruiting
- Study sites: 1 to 45
- Start date changed from estimate of Oct 25, 2024 to Nov 13, 2024
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Overall survival (OS)
Timeframe: Up to approximately 32 months from first patient in
Secondary (11)
Progression-Free Survival (PFS) assessed by evaluated by investigator
Objective response rate (ORR) evaluated by investigator
Disease control rate (DCR)
Time to response (TTR)
Duration of response (DOR)
Show 6 moreShow less
6 month PFS rate
12 month PFS rate
12 month OS rate
Incidence and severity of Adverse Event (AE) according to CTCAE 5.0
Anti-drug antibody (ADA)
Health related quality of life (HRQoL)
Arms and interventions
PM8002+PaclitaxelExperimental
Subjects will be administered with PM8002 in combination with Paclitaxel via intravenously (IV) infusion.
ChemotherapyActive comparator
Subjects will be administered with Investigator's Choice(Topotecan or Paclitaxel) via intravenously (IV) infusion Q3W.
Drugs: PM8002, Paclitaxel, Topotecan
Sites
45 sites in 1 country